サンプル依頼リスト カート
  • English
  • Korean
表紙：がんコンパニオン診断の世界市場規模調査・予測：提供別、技術別、疾患タイプ別、最終用途別、地域別分析、2023-2030年
市場調査レポート
商品コード
1407965

がんコンパニオン診断の世界市場規模調査・予測：提供別、技術別、疾患タイプ別、最終用途別、地域別分析、2023-2030年

Global Oncology Companion Diagnostic Market Size Study & Forecast, by Offerings, by Technology, By Disease Type, By End-Use, and Regional Analysis, 2023-2030

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
がんコンパニオン診断の世界市場規模調査・予測：提供別、技術別、疾患タイプ別、最終用途別、地域別分析、2023-2030年
出版日: 2023年12月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがんコンパニオン診断市場は、2022年に約31億米ドルと評価され、予測期間2023-2030年には12.9％以上の健全な成長率で成長すると予測されています。

がんコンパニオン診断（CDx）は、患者の腫瘍における特定の特徴や分子変化を同定するために使用される医療検査やバイオマーカーの一種です。これらの特性は、しばしば特定の標的療法やがんの治療に対する患者の奏効の可能性に関連します。がんコンパニオン診断の主な目的は、医療プロバイダーががん患者に対してより個別化された効果的な治療方針を決定する手助けをすることです。標的を絞ったがん治療やオーダーメイドの薬剤に対する需要の急増、製薬業界における投資の増加、コンパニオン診断の承認率の上昇が、世界中で市場の需要を促進している最も顕著な要因です。

さらに、高齢化や不健康なライフスタイルなどの要因により、がんの罹患率は世界的に上昇しています。このことが、がんコンパニオン診断に対するより大きな需要を生み出しています。世界保健機関（WHO）によると、2020年には世界で約1,930万人の新規がん症例が記録されたと推定されており、この症例数は増加し、2040年には3,020万人に達すると予測されています。さらに、診断薬事業体と製薬事業体との協力関係の増加や、研究開発活動への投資の増加は、予測期間中に様々な有利な機会をもたらします。しかし、開発・検査コストの高さと規制上の課題が、2023-2030年の予測期間を通じて市場の成長を妨げています。

がんコンパニオン診断の世界市場調査において考慮された主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、精密医療における進歩の高まり、標的がん治療の開発、標的治療と個別化医療に対する製薬業界の焦点の高まりにより、2022年の市場を独占しました。一方、アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予想されています。精密医療およびゲノム研究を推進する政府および医療業界のイニシアティブの増加と、診断技術およびツールの継続的な進歩が、コンパニオン診断の開発と改良に寄与し、同地域全体の市場需要を大きく促進しています。

本調査の目的は、近年における様々なセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 がんコンパニオン診断の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 業界の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 がんコンパニオン診断の世界市場力学

  • がんコンパニオン診断市場の影響分析（2020-2030年）
    • 市場促進要因
      • 標的がん治療とテーラーメイド薬剤の需要急増
      • がん罹患率の上昇
    • 市場の課題
      • 開発・検査コストの高さ
      • 規制上の課題
    • 市場機会
      • 診断薬と製薬企業間の提携の増加
      • 研究開発への投資の増加

第4章 がんコンパニオン診断の世界市場：産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 がんコンパニオン診断の世界市場：提供別

  • 市場スナップショット
  • がんコンパニオン診断の世界市場：提供別、実績 - ポテンシャル分析
  • がんコンパニオン診断の世界市場：提供別推定・予測、2020-2030年
  • がんコンパニオン診断市場、サブセグメント分析
    • 機器
    • 消耗品
    • ソフトウェア
    • サービス

第6章 がんコンパニオン診断の世界市場：技術別

  • 市場スナップショット
  • がんコンパニオン診断の世界市場：技術別、実績 - ポテンシャル分析
  • がんコンパニオン診断の世界市場：技術別推定・予測、2020-2030年
  • がんコンパニオン診断市場、サブセグメント分析
    • ポリメラーゼ連鎖反応（PCR）
    • 次世代シーケンシング（NGS）
    • 免疫組織化学（IHC）
    • In Situハイブリダイゼーション（ISH）/蛍光In Situハイブリダイゼーション（FISH）
    • その他

第7章 がんコンパニオン診断の世界市場：疾患タイプ別

  • 市場スナップショット
  • がんコンパニオン診断の世界市場：疾患タイプ別、実績 - ポテンシャル分析
  • がんコンパニオン診断の世界市場：疾患タイプ別推定・予測、2020-2030年
  • がんコンパニオン診断市場、サブセグメント分析
    • 乳がん
    • 非小細胞肺がん
    • 大腸がん
    • 白血病
    • 黒色腫
    • 前立腺がん
    • その他

第8章 がんコンパニオン診断市場：最終用途別

  • 市場スナップショット
  • がんコンパニオン診断の世界市場：最終用途別、実績 - ポテンシャル分析
  • がんコンパニオン診断の世界市場：最終用途別推定・予測2020-2030年
  • がんコンパニオン診断市場、サブセグメント分析
    • 病院
    • 病理/診断研究所
    • 学術医療センター

第9章 がんコンパニオン診断の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • がんコンパニオン診断市場、地域別市場スナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東・アフリカ

第10章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Agilent Technologies, Inc.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Illumina, Inc.
    • QIAGEN N.V.
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • ARUP Laboratories
    • Abbott Laboratories
    • Myriad Genetics, Inc.
    • bioMerieux SA
    • Invivoscribe, Inc.

第11章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Oncology Companion Diagnostic Market, report scope
  • TABLE 2. Global Oncology Companion Diagnostic Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Oncology Companion Diagnostic Market estimates & forecasts by Offerings 2020-2030 (USD Billion)
  • TABLE 4. Global Oncology Companion Diagnostic Market estimates & forecasts by Technology 2020-2030 (USD Billion)
  • TABLE 5. Global Oncology Companion Diagnostic Market estimates & forecasts by Disease Type 2020-2030 (USD Billion)
  • TABLE 6. Global Oncology Companion Diagnostic Market estimates & forecasts by End-use 2020-2030 (USD Billion)
  • TABLE 7. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. U.S. Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. U.S. Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. Canada Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. Canada Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. UK Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. UK Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. Germany Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. Germany Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. France Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. France Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Italy Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Italy Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. Spain Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. Spain Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. RoE Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. RoE Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. China Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. China Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. India Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. India Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. Japan Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. Japan Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. South Korea Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. South Korea Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. Australia Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. Australia Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Brazil Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Brazil Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. Mexico Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. Mexico Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. RoLA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoLA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. Saudi Arabia Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 69. South Africa Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. RoMEA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 71. List of secondary sources, used in the study of global Oncology Companion Diagnostic Market
  • TABLE 72. List of primary sources, used in the study of global Oncology Companion Diagnostic Market
  • TABLE 73. Years considered for the study
  • TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Oncology Companion Diagnostic Market, research methodology
  • FIG 2. Global Oncology Companion Diagnostic Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Oncology Companion Diagnostic Market, key trends 2022
  • FIG 5. Global Oncology Companion Diagnostic Market, growth prospects 2023-2030
  • FIG 6. Global Oncology Companion Diagnostic Market, porters 5 force model
  • FIG 7. Global Oncology Companion Diagnostic Market, pest analysis
  • FIG 8. Global Oncology Companion Diagnostic Market, value chain analysis
  • FIG 9. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Oncology Companion Diagnostic Market, regional snapshot 2020 & 2030
  • FIG 15. North America Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Oncology Companion Diagnostic Market is valued at approximately USD 3.1 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 12.9% over the forecast period 2023-2030. An oncology Companion Diagnostic (CDx) is a type of medical test or biomarker that is used to identify specific characteristics or molecular alterations in a patient's tumor. These characteristics are often associated with the patient's likelihood of responding to a particular targeted therapy or treatment for cancer. The primary purpose of oncology companion diagnostics is to aid healthcare providers in making more personalized and effective treatment decisions for cancer patients. The surge in demand for targeted cancer treatment and tailored drugs, growing investments in the pharmaceutical industry, coupled with the rise in approval rate for companion diagnostics are the most prominent factors that are propelling the market demand across the globe.

Additionally, the incidence of cancer is rising worldwide, due to factors such as an aging population and unhealthy lifestyles. This is creating a greater demand for oncology companion diagnostics. According to the World Health Organization, in 2020, it was estimated that nearly 19.3 million new cases of cancer were recorded globally, which is projected to rise and is likely to reach 30.2 million new cases by 2040. Moreover, the increasing collaborations between diagnostic and pharma entities, as well as the growing investment in research and development activities present various lucrative opportunities over the forecast years. However, the high cost of development and testing and the regulatory challenges are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Oncology Companion Diagnostic Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising advancements in precision medicine, a growing development of targeted cancer therapies, as well as the growing focus of the pharmaceutical industry on targeted therapies and personalized medicine. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing number of government and healthcare industry initiatives promoting precision medicine and genomic research, coupled with ongoing advancements in diagnostic technologies and tools contribute to the development and improvement of companion diagnostics that are significantly propelling the market demand across the region.

Major market players included in this report are:

  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories
  • Abbott Laboratories
  • Myriad Genetics, Inc.
  • bioMerieux SA
  • Invivoscribe, Inc.

Recent Developments in the Market:

  • In July 2020, The Ventana HER2 Dual ISH DNA Probe Cocktail assay received approval from the FDA as a revolutionary fast way to identify the HER2 biomarker for breast cancer and as a complementary diagnosis for Herceptin therapy.
  • In August 2020, The FDA approved the FoundationOne Liquid CDx, a pan-tumor liquid biopsy test, and the Guardant360 CDx assay, an NGS test that employs circulating cell-free DNA as a CDx. Both tests, Guardant360 CDx and FoundationOne Liquid CDx, serve dual purposes as companion diagnostic tests and for general tumor profiling. A companion diagnostic test provides essential information about the safe and effective use of a corresponding drug, indicating whether a patient's tumor has a genetic change targeted by a specific drug. Notably, Guardant360 CDx is approved as a companion diagnostic for osimertinib (Tagrisso), a lung cancer therapy, while FoundationOne Liquid CDx holds approval for three lung cancer therapies and a prostate cancer therapy. Ongoing clinical studies aim to support additional companion diagnostic labels for both tests.

Global Oncology Companion Diagnostic Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Offerings, Technology, Disease Type, End-use, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Offerings:

  • Instrument
  • Consumables
  • Software
  • Services

By Technology:

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
  • Other Technologies

By Disease Type:

  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma
  • Prostate Cancer
  • Others

By End-Use:

  • Hospital
  • Pathology/Diagnostic Laboratory
  • Academic Medical Center

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Oncology Companion Diagnostic Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Oncology Companion Diagnostic Market, by Offerings, 2020-2030 (USD Billion)
    • 1.2.3. Oncology Companion Diagnostic Market, by Technology, 2020-2030 (USD Billion)
    • 1.2.4. Oncology Companion Diagnostic Market, by Disease Type, 2020-2030 (USD Billion)
    • 1.2.5. Oncology Companion Diagnostic Market, by End-use, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Oncology Companion Diagnostic Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Oncology Companion Diagnostic Market Dynamics

  • 3.1. Oncology Companion Diagnostic Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Surge in demand for targeted cancer treatment and tailored drugs
      • 3.1.1.2. Rising incidence of cancer
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of development and testing
      • 3.1.2.2. Regulatory challenges
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing collaborations between diagnostic and pharma entities
      • 3.1.3.2. Growing investment in the research and development activities

Chapter 4. Global Oncology Companion Diagnostic Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Oncology Companion Diagnostic Market, by Offerings

  • 5.1. Market Snapshot
  • 5.2. Global Oncology Companion Diagnostic Market by Offerings, Performance - Potential Analysis
  • 5.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Offerings 2020-2030 (USD Billion)
  • 5.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
    • 5.4.1. Instrument
    • 5.4.2. Consumables
    • 5.4.3. Software
    • 5.4.4. Services

Chapter 6. Global Oncology Companion Diagnostic Market, by Technology

  • 6.1. Market Snapshot
  • 6.2. Global Oncology Companion Diagnostic Market by Technology, Performance - Potential Analysis
  • 6.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
  • 6.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
    • 6.4.1. Polymerase Chain Reaction (PCR)
    • 6.4.2. Next-Generation Sequencing (NGS)
    • 6.4.3. Immunohistochemistry (IHC)
    • 6.4.4. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
    • 6.4.5. Other Technologies

Chapter 7. Global Oncology Companion Diagnostic Market, by Disease Type

  • 7.1. Market Snapshot
  • 7.2. Global Oncology Companion Diagnostic Market by Disease Type, Performance - Potential Analysis
  • 7.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
  • 7.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
    • 7.4.1. Breast cancer
    • 7.4.2. Non-small cell lung cancer
    • 7.4.3. Colorectal cancer
    • 7.4.4. Leukemia
    • 7.4.5. Melanoma
    • 7.4.6. Prostate cancer
    • 7.4.7. Others

Chapter 8. Oncology Companion Diagnostic Market, by End-use

  • 8.1. Market Snapshot
  • 8.2. Global Oncology Companion Diagnostic Market by End-use, Performance - Potential Analysis
  • 8.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by End-use 2020-2030 (USD Billion)
  • 8.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
    • 8.4.1. Hospital
    • 8.4.2. Pathology/Diagnostic laboratory
    • 8.4.3. Academic medical center

Chapter 9. Global Oncology Companion Diagnostic Market, Regional Analysis

  • 9.1. Top Leading Countries
  • 9.2. Top Emerging Countries
  • 9.3. Oncology Companion Diagnostic Market, Regional Market Snapshot
  • 9.4. North America Oncology Companion Diagnostic Market
    • 9.4.1. U.S. Oncology Companion Diagnostic Market
      • 9.4.1.1. Offerings breakdown estimates & forecasts, 2020-2030
      • 9.4.1.2. Technology breakdown estimates & forecasts, 2020-2030
      • 9.4.1.3. Disease Type breakdown estimates & forecasts, 2020-2030
      • 9.4.1.4. End-use breakdown estimates & forecasts, 2020-2030
    • 9.4.2. Canada Oncology Companion Diagnostic Market
  • 9.5. Europe Oncology Companion Diagnostic Market Snapshot
    • 9.5.1. U.K. Oncology Companion Diagnostic Market
    • 9.5.2. Germany Oncology Companion Diagnostic Market
    • 9.5.3. France Oncology Companion Diagnostic Market
    • 9.5.4. Spain Oncology Companion Diagnostic Market
    • 9.5.5. Italy Oncology Companion Diagnostic Market
    • 9.5.6. Rest of Europe Oncology Companion Diagnostic Market
  • 9.6. Asia-Pacific Oncology Companion Diagnostic Market Snapshot
    • 9.6.1. China Oncology Companion Diagnostic Market
    • 9.6.2. India Oncology Companion Diagnostic Market
    • 9.6.3. Japan Oncology Companion Diagnostic Market
    • 9.6.4. Australia Oncology Companion Diagnostic Market
    • 9.6.5. South Korea Oncology Companion Diagnostic Market
    • 9.6.6. Rest of Asia Pacific Oncology Companion Diagnostic Market
  • 9.7. Latin America Oncology Companion Diagnostic Market Snapshot
    • 9.7.1. Brazil Oncology Companion Diagnostic Market
    • 9.7.2. Mexico Oncology Companion Diagnostic Market
  • 9.8. Middle East & Africa Oncology Companion Diagnostic Market
    • 9.8.1. Saudi Arabia Oncology Companion Diagnostic Market
    • 9.8.2. South Africa Oncology Companion Diagnostic Market
    • 9.8.3. Rest of Middle East & Africa Oncology Companion Diagnostic Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
    • 10.1.1. Company 1
    • 10.1.2. Company 2
    • 10.1.3. Company 3
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. Agilent Technologies, Inc.
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Recent Developments
    • 10.3.2. Illumina, Inc.
    • 10.3.3. QIAGEN N.V.
    • 10.3.4. Thermo Fisher Scientific, Inc.
    • 10.3.5. F. Hoffmann-La Roche Ltd.
    • 10.3.6. ARUP Laboratories
    • 10.3.7. Abbott Laboratories
    • 10.3.8. Myriad Genetics, Inc.
    • 10.3.9. bioMerieux SA
    • 10.3.10. Invivoscribe, Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption